Literature DB >> 22511140

Meta-analysis of subclavian insertion and nontunneled central venous catheter-associated infection risk reduction in critically ill adults.

Jean-Jacques Parienti1, Damien du Cheyron, Jean-François Timsit, Ousmane Traoré, Pierre Kalfon, Olivier Mimoz, Leonard A Mermel.   

Abstract

OBJECTIVE: Catheter-associated infections are common, costly, and potentially lethal. The impact of catheter insertion site on infection risk remains controversial. We aimed to establish whether nontunneled central venous catheters inserted in the subclavian vein are associated with lower risk of catheter-associated infection compared to femoral or internal jugular vein insertion. DATA SOURCES: We searched MEDLINE (2000-2011), EMBASE (2000-2011), and Cochrane Library plus meta-analyses, gray literature, reference lists, and articles recommended by experts. STUDY SELECTION AND EXTRACTION: We selected peer-reviewed, randomized, or prospective cohort studies with systematic catheter culture using semiquantitative or quantitative catheter culture techniques and data available for catheter-associated infection by insertion site. Two reviewers independently performed study selection, assessed study quality, and extraction. Discrepancies were resolved by discussion and consensus. Outcomes were mean catheter duration and catheter-associated infection expressed as incidence density per 1000 catheter days. DATA SYNTHESIS: Ten studies (3250 subclavian, 3053 internal jugular, and 1554 femoral vein) met the inclusion criteria, one of which was randomized (136 subclavian vein and 134 femoral vein). Subclavian vein catheters were left in place significantly longer than alternative catheters (mean difference: 2 days, 95% confidence interval [0.9-3.1], I=92%, p<.001). The subclavian vein site was associated with fewer catheter-associated infections (1.3 compared to 2.7 per 1000 catheter days for alternative sites, incidence density ratio 0.50; 95% confidence interval [0.33- 0.74], I=0%, p<.001). The same was true when comparisons were stratified by alternative sites (subclavian vein vs. internal jugular vein, incidence density ratio 0.46; 95% confidence interval [0.30-0.70], I=0%; subclavian vein vs. femoral vein, incidence density ratio 0.27; 95% confidence interval [0.15-0.48], I=31%).
CONCLUSION: Shortcomings in study design, including channeling, confounding bias, and study heterogeneity, may limit the interpretation of our preliminary study results. Our analysis suggests that the subclavian site may be associated with a lower risk of catheter-associated infection. However, a large, randomized, controlled trial comparing each catheter site complication is warranted before the subclavian site can be unequivocally recommended as a first choice for central venous catheter insertion.

Entities:  

Mesh:

Year:  2012        PMID: 22511140     DOI: 10.1097/CCM.0b013e31823e99cb

Source DB:  PubMed          Journal:  Crit Care Med        ISSN: 0090-3493            Impact factor:   7.598


  16 in total

1.  A randomized clinical trial of ultrasound-guided infra-clavicular cannulation of the subclavian vein in cardiac surgical patients: short-axis versus long-axis approach.

Authors:  Antonella Vezzani; Tullio Manca; Claudia Brusasco; Gregorio Santori; Luca Cantadori; Andrea Ramelli; Gianluca Gonzi; Francesco Nicolini; Tiziano Gherli; Francesco Corradi
Journal:  Intensive Care Med       Date:  2017-03-13       Impact factor: 17.440

Review 2.  [Infection prevention by the anesthesia team].

Authors:  S Schulz-Stübner
Journal:  Anaesthesist       Date:  2013-01       Impact factor: 1.041

3.  Cannulation of the subclavian vein using real-time ultrasound guidance.

Authors:  Thomas W Davies; Hugh Montgomery; Edward Gilbert-Kawai
Journal:  J Intensive Care Soc       Date:  2020-01-23

4.  Health Care-Associated Infective Endocarditis: a Growing Entity that Can Be Prevented.

Authors:  Natividad Benito; Juan M Pericas; Mercè Gurguí; Carlos A Mestres; Francesc Marco; Asunción Moreno; Juan P Horcajada; José M Miró
Journal:  Curr Infect Dis Rep       Date:  2014-11       Impact factor: 3.725

Review 5.  Prevention of Central Line-Associated Bloodstream Infections.

Authors:  Taison Bell; Naomi P O'Grady
Journal:  Infect Dis Clin North Am       Date:  2017-07-05       Impact factor: 5.982

Review 6.  Long-term vascular access in differently resourced settings: a review of indications, devices, techniques, and complications.

Authors:  Karen Milford; Dirk von Delft; Nkululeko Majola; Sharon Cox
Journal:  Pediatr Surg Int       Date:  2020-03-21       Impact factor: 1.827

7.  Evaluation of Skin Colonisation And Placement of vascular access device Exit sites (ESCAPE Study).

Authors:  Nancy L Moureau; Nicole Marsh; Li Zhang; Michelle J Bauer; Emily Larsen; Gabor Mihala; Amanda Corley; India Lye; Marie Cooke; Claire M Rickard
Journal:  J Infect Prev       Date:  2018-11-09

8.  Renal replacement therapy in adult and pediatric intensive care : Recommendations by an expert panel from the French Intensive Care Society (SRLF) with the French Society of Anesthesia Intensive Care (SFAR) French Group for Pediatric Intensive Care Emergencies (GFRUP) the French Dialysis Society (SFD).

Authors:  Christophe Vinsonneau; Emma Allain-Launay; Clarisse Blayau; Michael Darmon; Damien Ducheyron; Theophile Gaillot; Patrick M Honore; Etienne Javouhey; Thierry Krummel; Annie Lahoche; Serge Letacon; Matthieu Legrand; Mehran Monchi; Christophe Ridel; René Robert; Frederique Schortgen; Bertrand Souweine; Patrick Vaillant; Lionel Velly; David Osman; Ly Van Vong
Journal:  Ann Intensive Care       Date:  2015-12-30       Impact factor: 6.925

Review 9.  A review in emergency central venous catheterization.

Authors:  Osaree Akaraborworn
Journal:  Chin J Traumatol       Date:  2017-05-17

10.  Incidence of catheter-related complications in patients with central venous or hemodialysis catheters: a health care claims database analysis.

Authors:  Pavel Napalkov; Diana M Felici; Laura K Chu; Joan R Jacobs; Susan M Begelman
Journal:  BMC Cardiovasc Disord       Date:  2013-10-16       Impact factor: 2.298

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.